Pulse Biosciences, Inc., a clinical-stage medical technology company headquartered in Hayward, California, disclosed in a US Securities and Exchange Commission filing that the company and several of its directors have received subpoenas from the SEC. According to Pulse, the SEC is seeking information about trading of the company’s stock in advance of the financing announcement made by the company in September 2017. Pulse says that it is cooperating with the investigation.
March 14, 2019
Medical technology company discloses SEC investigation
Related by Topic
Arizona resident reaches settlement with SEC to resolve insider trading charges
August 28, 2025
News Alert
SEC charges former biopharma director and his friends and relatives with insider trading
August 27, 2025
News Alert
SEC charges Dallas resident with insider trading
August 13, 2025
News Alert